Form 4: Revolution Medicines CEO Sells Shares to Cover Tax Obligations
SEC Form 4
Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,714 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- Mark A. Goldsmith, the President and CEO of Revolution Medicines, Inc., sold 11,714 shares of common stock on December 16, 2024.
- The sale was executed at a price of $45.4038 per share.
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
- Following the transaction, Goldsmith directly owns 325,056 shares.
- Goldsmith also indirectly owns shares through several trusts: 20,424 shares held by the Jonathan Goldsmith Revocable Trust, 20,424 shares held by the Rebecca Eve Goldsmith Trust, and 465,604 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Insider sales, especially those related to tax obligations, are common and generally don't indicate a negative outlook for the company. The use of a pre-arranged 10b5-1 trading plan suggests the sale was planned and not based on current market conditions or inside information.
Key Dates
| Date | Description |
|---|---|
| December 15, 2011 | Date of the Goldsmith Children's 2011 Irrevocable Education Trust |
| May 31, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| July 15, 2023 | Date after which the Rule 10b5-1 trading plan was active |
| December 16, 2024 | Date of the stock sale transaction |
| December 18, 2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.